CD163 and kidney disorder: We anticipate that intensive research in the field of biomarkers, including plasma [69] and urine [70–77] mediators such as TWEAK, VCAM-1, CD163, and matrix metalloproteinases, will be fruitful and provide novel non-invasive tools to monitor renal disease activity, thus enabling prognostication and treatment tailoring in patients with LN.